Algernon Pharmac Stock Price, News & Analysis

Algernon Pharmaceuticals Inc. has announced the database lock for its Phase 2 proof-of-concept study of NP-120 (Ifenprodil) targeting idiopathic pulmonary fibrosis (IPF) and chronic cough. The trial, which began in 2020 and enrolled 20 patients, aims to assess Ifenprodil's safety and efficacy. Topline data is expected in July 2022, with primary endpoints focusing on lung function and cough reduction. The study includes subgroup analysis based on cough counts and serum biomarkers of fibrosis.

Algernon Pharmaceuticals has announced the completion of patient treatment in its Phase 2 proof-of-concept study of NP-120 (Ifenprodil) for idiopathic pulmonary fibrosis (IPF) and chronic cough. Topline data is expected in July 2022. The trial enrolled 20 patients to assess Ifenprodil's safety and efficacy, focusing on lung function and cough reduction. The company aims to provide insights into the drug’s unique mechanism against current treatments, highlighting a pressing need for new options in managing IPF, which has a high mortality rate within 3-4 years.

Algernon Pharmaceuticals has announced promising results from a preclinical study of its lead compound, NP-251 (Repirinast), which demonstrated a significant 56% reduction in fibrosis related to chronic kidney disease (CKD) and non-alcoholic steatohepatitis (NASH) in animal models. The study showed statistical significance in the results, with strong implications for Repirinast’s potential as an anti-fibrotic treatment across various diseases. The company plans to advance Repirinast into a Phase 1 clinical trial, supported by a well-established safety history in the Japanese market.

Algernon Pharmaceuticals announced a contract with Zhejiang Ausun Pharmaceutical to manufacture cGMP supply of its repurposed drug NP-251 (Repirinast). This drug, previously used for asthma in Japan, showed a 50% reduction in kidney fibrosis in preclinical trials. The company initiated a new CKD research program, aiming for human trials following a bridging toxicity study. Global CKD drug market expected to grow from $11.5 billion in 2015 to $15.8 billion by 2024. Algernon plans trials in Australia and the U.S., leveraging tax credits for research costs.

Algernon Pharmaceuticals has successfully completed enrollment in its Phase 2 study for NP-120 (Ifenprodil), targeting idiopathic pulmonary fibrosis (IPF) and chronic cough. This proof-of-concept trial includes 20 patients across 7 sites in Australia and New Zealand. Ifenprodil aims to assess the preservation of lung function and cough relief in IPF patients. A data readout is projected for Q2 2022. The drug has demonstrated anti-inflammatory properties and reduced cough frequency in preclinical models, positioning Algernon for potential advancements in IPF treatment.

Algernon Pharmaceuticals has received a Notice of Allowance for patent application No. 3101853 in Canada, covering methods for treating idiopathic pulmonary fibrosis (IPF) using Ifenprodil. The company has filed similar applications worldwide, including the U.S., Europe, China, and Japan. This marks a significant milestone in Algernon's drug repurposing strategy. Ifenprodil, an NMDA receptor antagonist, is currently being studied in a Phase 2 trial for its efficacy in preserving lung function in IPF patients. This progress reinforces Algernon's commitment to exploring new applications for existing drugs.

Algernon Pharmaceuticals has filed patent applications for novel salt forms of N,N-Dimethyltryptamine (DMT), enhancing its intellectual property portfolio. These novel salts aim to improve the drug's efficacy, safety, and stability. The company is also progressing in its planned Phase 1 DMT clinical human stroke study, having filed for regulatory approval in the UK. Previous studies suggest DMT may promote brain recovery following injury. Algernon focuses on repurposing safe, approved drugs to create new therapeutic applications.

Algernon Pharmaceuticals Inc. has submitted a combined Clinical Trials and Ethics Approval application to the UK Medicines and Healthcare Products Regulatory Agency for a Phase 1 study of AP-188 (DMT). This study aims to assess the safety, tolerability, and pharmacokinetics of DMT through prolonged intravenous infusion, involving 96 healthy volunteers. Positive feedback was previously received from the UK MHRA regarding the proposed DMT Stroke study. This research will inform future Phase 2 studies targeting acute stroke and rehabilitation patients.

Algernon Pharmaceuticals (CSE: AGN, OTCQB: AGNPF) announced positive feedback from the U.S. FDA regarding its pre-Investigational New Drug (pre-IND) meeting for NP-120 (Ifenprodil) targeting chronic cough treatment. The FDA provided guidance on the Phase 2b study protocol and requested genotoxicity testing, estimated to take 90 days. Interim data from a previous study indicated a trend toward reduced cough counts in patients. Ifenprodil demonstrated significant efficacy in preclinical studies, outperforming Merck's gefapixant in cough reduction.